Edwards Lifesciences Corporation(EW)

New York Stock Exchange
Sector: Healthcare | Industry: Medical - Devices
Edwards Lifesciences Corporation logo

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Latest News & Analysis

Edwards Lifesciences: Aortic Stenosis, TMTT Growth, and Competitive Analysis - Insights for Investors in Structural Heart Innovations. TAVR and TMTT Market Trends.
Apr 9, 2025

Edwards Lifesciences (EW): Aortic Stenosis, TMTT Growth, and Market Dynamics

Analysis of Edwards Lifesciences (EW): Aortic stenosis treatment, TMTT growth, competition, and market dynamics. Key insights for investors and analysts.

Read more →
Edwards Lifesciences: Advancing heart valve treatments with innovative TAVR technology for improved patient outcomes in structural heart disease.
Apr 2, 2025

Edwards Lifesciences (EW): TAVR, Valve Repair, and Market Analysis

Analysis of Edwards Lifesciences' advancements in structural heart disease treatment, market dynamics, and competitive landscape. Focus on TAVR, valve repair, and monitoring.

Read more →
Edwards Lifesciences (EW) stock analysis: TAVR slowdown, Intuitive Ventures competition, and strategic outlook.
Mar 24, 2025

Edwards Lifesciences (EW): Growth, Challenges & Market Outlook

Edwards Lifesciences (EW) faces TAVR slowdown and competition despite strong financials. Strategic initiatives are crucial for future success.

Read more →
Edwards Lifesciences: Navigating Growth in the Structural Heart Market - Q4 2024 Performance and Strategic Outlook
Mar 3, 2025

Edwards Lifesciences: Q4 2024 Performance, TAVR/TMTT Growth

Edwards Lifesciences navigates the structural heart market with Q4 2024 results, TAVR/TMTT growth, and a strategic outlook. Upcoming TD Cowen conference insights.

Read more →
Edwards Lifesciences Q4 2024 earnings analysis: TAVR/TMTT growth, market outlook, and strategic insights.
Feb 27, 2025

Edwards Lifesciences: Q4 2024 Earnings, TAVR/TMTT Growth & Market Outlook

Edwards Lifesciences (EW) Q4 2024 earnings beat expectations, driven by TAVR/TMTT growth. Margins face pressure, but analysts see long-term strength.

Read more →
Edwards Lifesciences Q4 2024 Analysis: Revenue Growth, TAVR, TMTT Performance, and Strategic Outlook for EW Stock
Feb 26, 2025

Edwards Lifesciences Q4 2024: Growth, Margins, and Outlook

Edwards Lifesciences' Q4 2024 results demonstrate strong growth in TAVR and TMTT. Strategic focus on structural heart and margin management are key.

Read more →
Edwards Lifesciences Q4 2024 earnings analysis, TAVR, TMTT growth, and 2025 outlook. Stock analysis and financial insights.
Feb 25, 2025

Edwards Lifesciences (EW): Q4 Earnings Analysis and 2025 Outlook

Edwards Lifesciences' Q4 2024 results reveal strong growth tempered by margin concerns. Focus shifts to structural heart and TMTT potential. Analyst outlook mixed. Strategic implications abound.

Read more →
Edwards Lifesciences analysis: Growth, margins, and market dynamics in 2025. Insights on TAVR, TMTT, and strategic shifts.
Feb 24, 2025

Edwards Lifesciences (EW): Growth, Margins, and Market Dynamics

Edwards Lifesciences' Q4 results show growth tempered by margin concerns. Strategic shifts and market dynamics shape the outlook for EW in 2025.

Read more →
Edwards Lifesciences Q4 2024 Results: Revenue growth, TAVR, TMTT, and strategic focus in structural heart disease. Analysis and investor perspective.
Feb 21, 2025

Edwards Lifesciences: Structural Heart Innovation Drives Q4 Growth Amidst Margin Concerns

Explore Edwards Lifesciences' Q4 2024 results, showcasing strong TAVR growth, TMTT innovation, and a strategic shift after divesting Critical Care.

Read more →
Edwards Lifesciences strategic shift to structural heart: Market analysis, Q4 2024 earnings review, TAVR, TMTT market dynamics, and financial outlook.
Feb 21, 2025

Edwards Lifesciences: A New Era in Structural Heart Strategy

Edwards Lifesciences focuses on structural heart strategy after critical care divestiture. Q4 earnings show strong growth, margin challenges, and TAVR/TMTT focus.

Read more →